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Abstract
Correction to Erik Serrao, Srinivas Odde, Kavya Ramkumar and Nouri Neamati: Raltegravir,
elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 2009,
6:25. Since the recent publication of our article (Neamati, Retrovirology 2009, 6:25), we have noticed
an error which we would like to correct and we would like to apologise to the readers for this
mistake.
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Correction
The structure of BMS-707035 has not been publicly
released. In Figure one on page 2 and a discussion on page
5 of our published paper [1], we mistakenly assigned a
structure and activity data to BMS-707035. The structure
and activity data that we mentioned actually belong to a
different compound from the same group. The resistance
pattern of BMS-707035 is "overlapping" rather than iden-
tical to raltegravir. Please see the following references [2,3]
for a detailed description of their development of pyrimi-
dine carboxamides.
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